



# Coverage determination request form.

EOC ID: MedImpact Opioid Review (200 MME)

Phone: 800-361-4542 Fax back to: 866-414-3453

MedImpact manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

**\*Please note that MedImpact will process the request as written, including drug name, with no substitution.**

Drug Name and Strength:

Expedited / Urgent

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

<p>Q1: Is this request for initial or continuing therapy?</p> <p><input type="checkbox"/> Initial therapy    <input type="checkbox"/> Continuing therapy</p>
<p>Q2: For CONTINUING THERAPY, please provide the start date (MM/YY):</p>
<p>Q3: Please indicate the patient's diagnosis for the requested medication:</p> <p><input type="checkbox"/> Pain secondary to a diagnosis of active cancer</p> <p><input type="checkbox"/> Pain secondary to a terminal illness</p> <p><input type="checkbox"/> Sickle-cell disease</p> <p><input type="checkbox"/> Acute pain: post-surgical pain</p> <p><input type="checkbox"/> Moderate-to-severe chronic pain</p> <p><input type="checkbox"/> Other</p>
<p>Q4: If the patient's diagnosis is OTHER, please specify below:</p>
<p>Q5: Does the prescriber attest to utilizing the safety measures outlined in the Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain?</p> <p><input type="checkbox"/> Yes    <input type="checkbox"/> No</p>

<p>Q6. Has the prescriber reviewed the appropriate state prescription drug monitoring program?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Missouri/Guam only: No, my state does not have an available prescription drug monitoring program</p>
<p>Q7. Has the patient been assessed for contraindications to opioid therapy (e.g. significant respiratory depression, known/suspected paralytic ileus, etc.)?</p> <p><input type="checkbox"/> Yes    <input type="checkbox"/> No</p>
<p>Q8. If patient is female between 18-45 years old, has the prescriber discussed risk of neonatal abstinence syndrome and provided counseling on contraceptive options?</p> <p><input type="checkbox"/> Yes    <input type="checkbox"/> No    <input type="checkbox"/> Not applicable</p>
<p>Q9. For post-surgical pain, has the patient been provided instruction on how to integrate their post-operative opioid therapy into their existing medication regimen (including titration of an existing opioid regimen)?</p> <p><input type="checkbox"/> Yes    <input type="checkbox"/> No    <input type="checkbox"/> The request is not for post-surgical pain</p>
<p>Q10. Has the patient been counseled on the risks of an opioid overdose and been provided with an opportunity to obtain a prescription or other access to naloxone in addition to their opioid prescriptions?</p> <p><input type="checkbox"/> Yes    <input type="checkbox"/> No</p>
<p>Q11. Does the prescriber attest that a cumulative daily MME (Morphine Milligram Equivalents) of 200 or greater is medically necessary for this patient?</p> <p><input type="checkbox"/> Yes    <input type="checkbox"/> No    <input type="checkbox"/> Not applicable</p>
<p>Q12. The prescriber may provide any additional rationale in order to justify coverage of the requested medication and quantity.</p>

---

Prescriber Signature \_\_\_\_\_ Date \_\_\_\_\_

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document